GO
Loading...

Teva Pharmaceutical Industries Ltd

More

  • TEL AVIV, Dec 11- Teva Pharmaceutical Industries forecast 2015 revenue below analysts' expectations, due to adverse foreign exchange moves and generic competition for its best-selling multiple sclerosis treatment Copaxone. There are two teams developing cheaper generic forms of Copaxone: one involving Novartis AG's Sandoz Inc and Momenta...

  • Merck committed to Cubist after patent losses Tuesday, 9 Dec 2014 | 9:29 AM ET

    Merck remains committed to its $8.4 billion acquisition of Cubist Pharmaceuticals even though a federal court invalidated most of the patents protecting the company's top-selling antibiotic just hours after that deal was announced Monday. The court upheld one patent that would stave off a cheaper generic version of the drug from rival Hospira Inc. until...

  • NEW YORK/ WINNIPEG, Dec 9- Valeant Pharmaceuticals International Inc is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt, boost its stock price and one day return to its traditional deal-making in a stronger position, people familiar with the matter told Reuters. Speculation about Valeant's next takeover target has...

  • NEW YORK/ WINNIPEG, Dec 9- Valeant Pharmaceuticals International Inc is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt, boost its stock price and one day return to its traditional deal-making in a stronger position, people familiar with the matter told Reuters. Speculation about Valeant's next takeover target has...

  • Dec 5- A Massachusetts jury has found that an agreement between AstraZeneca Plc and Ranbaxy Laboratories Ltd to delay the launch of a generic version of AstraZeneca's heartburn drug Nexium was not anticompetitive. AstraZeneca and an attorney for Ranbaxy released statements saying they were pleased with the verdict. The lawsuit, which began in 2012,...

  • Teva Pharma names Peterburg new chairman Wednesday, 26 Nov 2014 | 1:39 PM ET

    Nov 26- The board of Teva Pharmaceutical Industries Ltd elected Yitzhak Peterburg as its chairman, succeeding Phillip Frost, who is due to step down at the end of the year. The company also appointed Sol Barer, the former chief executive of Celgene Corp, as a director. Teva stock was up 0.8 percent at $57.02 on the New York Stock Exchange.

  • WASHINGTON, Oct 15- The U.S. Supreme Court on Wednesday appeared closely divided as it weighed Teva Pharmaceutical Industries Ltd's high-profile fight with generic drug manufacturers over patent protections for Copaxone, its top-selling multiple sclerosis drug. Israel- based Teva is battling to protect a key patent for the $4- billion- a-year MS drug that is...

  • WASHINGTON, Oct 15- The U.S. Supreme Court on Wednesday appeared closely divided as it weighed Teva Pharmaceutical Industries Ltd's high-profile fight with generic drug manufacturers over patent protections for Copaxone, its top-selling multiple sclerosis drug. The $4- billion- a-year drug accounts for 50 percent of Teva profits, and the patent fight is one...

  • WASHINGTON, Oct 15- The U.S. Supreme Court on Wednesday is set to wade into Teva Pharmaceutical Industries Ltd's fight over patent protections for Copaxone, its top-selling multiple sclerosis drug, in one of the most important business cases of the justices' new term. There are two teams developing cheaper generic forms of Copaxone: one involving Novartis AG's...

  • Oct 8- Amgen Inc said its copycat version of AbbVie Inc's blockbuster biotech drug Humira showed comparable safety and ability to generate immune response in patients with a type of skin disease. "We remain bullish about AMGN's biosimilar prospects given the manufacturing expertise which would likely be key for success in biosimilar competition," Deutsche...

  • Oct 3- The U.S. Supreme Court's new term is due to begin on Monday. *Texas Department of Housing and Community Affairs v. In July 2013, the appeals court ruled in favor of two teams developing cheaper generic forms of Copaxone: one involving Novartis AG's Sandoz Inc and Momenta Pharmaceuticals Inc and another involving Mylan Inc and Natco Pharma Ltd..

  • WASHINGTON, Oct 3- Gay marriage may be the most anticipated issue heading for the U.S. Supreme Court, but the justices also must tackle a host of business cases as they convene for their new term, including a patent battle involving Teva Pharmaceutical Industries Ltd.. The case also has broader ramifications in the patent arena as shown by the number of businesses...

  • *Expects key drug launches in fourth quarter despite FDA delay. Aug 7- Political opposition to tax-inversion deals will not stop Mylan Inc's purchase of some non-U.S. businesses from Abbott Laboratories, Chief Executive Heather Bresch said, even as some companies have backed away from such tax arrangements.

  • *Cuts top end of FY earnings forecast to $3.45/ shr from $3.60/ shr. Aug 7- Mylan Inc shaved the top end of its full-year revenue and earnings forecasts, citing delays in approval from the U.S. Food and Drug Administration for key generic drugs that it plans to launch this year.

  • *Q2 EPS ex-items $1.23 vs $1.22 forecast. *Now sees 2014 EPS $4.50- $4.80 with Copaxone competition. TEL AVIV, July 31- Teva Pharmaceutical Industries raised its full-year profit forecast on Thursday after posting higher quarterly earnings that were due in part to the launch of several generic products in the United States.

  • JERUSALEM, July 31- Israeli industrialist Benny Landa said his campaign to improve corporate governance at Teva Pharmaceutical Industries was delivering results, despite losing a shareholder vote at the world's largest generic drugmaker.

  • War and peace, and Israel's stock market Monday, 28 Jul 2014 | 9:07 AM ET
    An Iron Dome short-range missile defense system, positioned near the northern city of Haifa in Israel

    The Israeli stock market is a good test for the old saying that war is good for the economy. Is it investing maxim or enduring myth?

  • Summer's busiest week for markets is here Friday, 25 Jul 2014 | 6:10 PM ET
    Traders work on the floor of the New York Stock Exchange (NYSE) on Friday.

    A crush of big cap earnings and arguably the most important economic reports until September make next week the busiest of the summer for markets.

  • However, the report from the Generic Pharmaceutical Association said REMS have been used to prevent generic drugmakers from getting branded medicine to test their own versions, which is required to win FDA approval.

  • U.S. sales of $585 million far exceeded Wall Street forecasts in the $485 million range. The drug is taking flight as patients with the progressive neurological disease move from injectable treatments to more convenient pills, including Novartis AG's Gilenya and Sanofi SA's Aubagio.